Europe Collagen Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Europe Collagen Market Trends and Insights

Aging population seeking joint care, skin, bone, and hair health solutions

Europe's demographic shift, characterized by the rapid growth of the 60-plus age group compared to the working-age population, is influencing supplement demand. The focus is shifting from multivitamins to targeted functional ingredients. According to data from the World Health Organization (WHO), by 2030, the global population aged 60 or older will reach 1.4 billion, representing a 34% increase from 2019 ^{[1]Source: World Health Organization, “Ageing and health,” who.int}. Europe is contributing significantly to this trend due to low fertility rates and increased life expectancy. Joint-health formulations containing Type II collagen peptides are gaining popularity as orthopedic specialists increasingly recommend them to reduce reliance on non-steroidal anti-inflammatory drugs. In February 2024, Evonik plans to launch Vecollage Fortify L, a liquid collagen peptide aimed at improving joint mobility. This launch is supported by clinical evidence showing that a daily intake of 10 grams of hydrolyzed collagen can enhance cartilage synthesis markers within 12 weeks. Claims related to skin elasticity and dermal hydration are particularly appealing to the 50-plus female demographic, who view collagen as a non-invasive alternative to cosmetic procedures. While applications for hair and bone health are still emerging, they are attracting research and development investments, especially in formulations combining collagen with biotin, silica, and vitamin D3 for synergistic benefits.

Shift toward preventive healthcare and holistic wellness approaches

National health systems in Germany, France, and the Netherlands are evaluating reimbursement models for preventive nutrition interventions. These regulatory developments support collagen supplements positioned for wellness maintenance rather than disease treatment. This shift is driven by financial pressures, as chronic musculoskeletal conditions place a significant burden on European healthcare systems. Policymakers are increasingly focusing on preventive measures to delay the onset of such conditions. Consumers are also adopting holistic wellness routines that integrate collagen with probiotics, adaptogens, and plant-based proteins. This trend signifies a move from single-ingredient supplementation to multi-functional product combinations. Gelita highlighted this development by presenting OPTIBAR and PeptENDURE at Food Ingredients Europe (Fi Europe) in December. These collagen peptides are tailored for sports nutrition and recovery, addressing the intersection of performance enhancement and preventive care. Furthermore, the expansion of telemedicine and personalized nutrition applications is enabling direct-to-consumer brands to offer collagen products alongside DNA-based dietary recommendations. This strategy bypasses traditional retail channels, allowing brands to achieve higher profit margins.

Growing preference for beauty-from-within nutricosmetics

France and Italy, which have traditionally been strong markets for topical skincare, are now seeing a shift toward ingestible beauty products. This change is supported by dermatological studies that link oral collagen peptides to measurable improvements in skin hydration and wrinkle reduction. A 2024 study published in Frontiers in Nutrition found that a daily intake of 2.5 grams of collagen peptides over 12 weeks increased dermal collagen density by 9% in women aged 45 to 65, offering clinical evidence that appeals to evidence-focused consumers. DSM-Firmenich's April 2025 launch of SYN-COLL CB peptide, a bioactive ingredient designed to stimulate collagen synthesis at the cellular level, highlights the industry's transition from commodity gelatin to precision peptides with proven efficacy. Nutricosmetics are also gaining traction through social media, where influencers aged 25 to 40 share visible skin improvement results, encouraging trial among previously skeptical demographics. Additionally, regulatory clarity under European Union (EU) Regulation 1924/2006 on nutrition and health claims has allowed brands to promote specific benefits, such as "supports skin elasticity," without risking enforcement actions. This reduced compliance risk has further encouraged investment in the category.

Rising popularity of clean-label and natural products

Nordic consumers, particularly in Sweden and Denmark, are increasingly prioritizing transparency in sourcing and processing. They prefer collagen derived from grass-fed bovine or wild-caught marine species over conventionally farmed alternatives. Lapi Gelatine's focus on European production and certifications, such as International Organization for Standardization (ISO) 22000, Food Safety System Certification (FSSC) 22000, Aquaculture Stewardship Council, and Friend of the Sea, highlights the importance of third-party validation in the premium segment. Clean-label requirements now extend beyond ingredient origin to include processing methods. Enzymatic hydrolysis is favored over acid or alkaline extraction due to its ability to avoid chemical residues and preserve native peptide structures. This trend is pressuring suppliers who cannot ensure traceability to the farm or fishery level, while benefiting vertically integrated companies that manage the supply chain from raw materials to finished peptides. Additionally, the United Kingdom's Food Safety Act 1990 and the Informed Sport certification program are establishing de facto standards that are being adopted by other European markets ^{[2]Source: Food Standard Agency, “Key regulations,” food.gov.uk}. This creates a regulatory framework that advantages large manufacturers capable of ensuring compliance.

Ethical concerns over animal-derived collagen welfare and sourcing

Animal-welfare advocacy groups in Germany and the United Kingdom (UK) are urging retailers to audit collagen supply chains for compliance with European Union (EU) Directive 98/58/EC on livestock protection. This has created reputational risks for brands unable to demonstrate humane slaughter practices. Bovine collagen sourced from cattle raised in intensive feedlots is facing boycotts from ethically conscious consumers, who prefer grass-fed or organic certifications despite their higher costs. Porcine collagen faces additional challenges due to religious and cultural restrictions, as Muslim and Jewish populations avoid porcine-derived products, limiting its market penetration in diverse urban centers such as London, Paris, and Berlin. Technological advancements, such as precision fermentation and recombinant collagen technologies, exemplified by Gelita's collaboration with Geltor, present opportunities for animal-free alternatives that replicate identical amino-acid sequences. However, as of 2026, commercial-scale production remains cost-prohibitive. Transparency initiatives, including blockchain-enabled traceability from farm to finished product, are emerging as competitive advantages. Nevertheless, the high implementation costs pose challenges for smaller suppliers. The ethical considerations surrounding collagen sourcing are becoming increasingly significant as younger consumers (aged 18 to 35) prioritize sustainability and animal welfare over price. This demographic shift is expected to influence sourcing strategies through 2031.

Allergenic risks from bovine, porcine, or marine sources

Collagen peptides, even after hydrolysis, retain allergenic epitopes that may trigger immune responses in sensitized individuals. Marine collagen presents specific risks for consumers with shellfish or fish allergies, and European Union (EU) Regulation 1169/2011 requires clear allergen labeling, which can discourage initial purchases ^{[3]Source: European Union, “Food Information to Consumers Regulation,” eur-lex.europa.eu}. Bovine collagen carries a residual risk of prion contamination, although no cases have been reported in collagen supplements. This risk contributes to consumer hesitancy in regions with a history of bovine spongiform encephalopathy outbreaks. Porcine collagen is generally well-tolerated but may cause cross-reactivity in individuals allergic to pork proteins. Clinical data on collagen allergenicity remain limited, with most reported adverse events involving gastrointestinal discomfort rather than severe allergic reactions like anaphylaxis. However, the lack of large-scale safety studies restricts widespread physician recommendations. Manufacturers are focusing on developing hypoallergenic formulations, such as extensively hydrolyzed peptides with molecular weights below 1,000 Daltons, which are believed to lower immunogenic potential. Regulatory bodies have not yet established standardized allergen testing protocols for collagen, leaving brands to self-regulate and assume liability risks.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Source: Marine Gains as Sustainability Trumps Cost

Animal-based collagen is projected to account for 66.14% of the European market volume in 2025, supported by well-established bovine and porcine supply chains and cost advantages ranging from 30% to 50% compared to marine alternatives. Bovine collagen, which is rich in Type I and Type III collagen, dominates applications in joint health and sports nutrition. Meanwhile, porcine collagen, known for its high glycine content, is preferred in cosmetic formulations aimed at improving skin elasticity. Marine-based collagen is anticipated to grow at a compound annual growth rate (CAGR) of 9.31% through 2031, driven by sustainability requirements and its perceived superior absorption due to smaller peptide sizes and a high concentration of Type I collagen.

Coastal nations such as Spain, Italy, and France are utilizing byproducts from the fishing industry to produce marine collagen, thereby reducing waste and adhering to certifications like the Aquaculture Stewardship Council and Friend of the Sea. These certifications enable premium pricing opportunities in Northern European markets. Emerging technologies, including precision fermentation and recombinant collagen production, represent a potential third category of collagen sources. Although still in the early stages of commercialization, these technologies could disrupt the traditional animal-versus-marine dichotomy by offering identical amino acid profiles without relying on animal inputs. For instance, Gelita's collaboration with Geltor highlights advancements in this area.

By Form: Liquid Formats Leverage Bioavailability Science

Powder collagen accounted for 81.12% of European revenue in 2025, driven by its cost efficiency, extended shelf life, and compatibility with existing supplement manufacturing processes. This format's dominance is particularly evident in Germany and the United Kingdom, where consumers prioritize value and are accustomed to incorporating supplements into beverages or smoothies. Meanwhile, liquid collagen is projected to grow at a compound annual growth rate (CAGR) of 8.89% through 2031, supported by advancements in liposomal encapsulation and colloidal delivery systems, which enhance absorption rates and bioavailability. For instance, Evonik's February 2024 launch of Vecollage Fortify L, a liquid peptide designed to improve joint mobility, leverages clinical evidence showing that liquid formats bypass gastric degradation more effectively than powders, allowing for lower dosages to achieve similar efficacy. Additionally, ready-to-drink collagen beverages are gaining popularity in France and Italy, where they are perceived as functional alternatives to traditional skincare routines, merging nutrition with cosmetics.

Powder formulations face challenges related to taste and texture, such as a gritty mouthfeel and residual odor, which can reduce consumer appeal. However, advancements in flavor-masking technologies, including microencapsulation and co-formulation with fruit extracts, are addressing these issues. Liquid collagen formats, while resolving sensory concerns, require preservatives and stabilizers to ensure shelf life, which can conflict with clean-label preferences and increase production costs. The growing shift toward liquid formats is also influenced by direct-to-consumer brands that utilize subscription models and premium pricing strategies to offset these higher costs. Capsule and tablet formats, though not separately segmented in the approved metrics, represent a third category that combines the stability of powders with the convenience of liquids, particularly for on-the-go consumption. For example, Gelita's EASYSEAL capsule technology, showcased at Fi Europe 2025, underscores the industry's focus on delivery innovations as a means of differentiation in a competitive market.

By Application: Dietary Supplements Outpace Cosmetics on Clinical Evidence

In 2025, personal care and cosmetics accounted for 42.83% of European collagen revenue, reflecting the sector's historical emphasis on topical anti-aging formulations and the influence of French and Italian beauty conglomerates. However, dietary supplements are projected to grow at a compound annual growth rate (CAGR) of 9.33% through 2031, driven by peer-reviewed studies linking oral collagen peptides to measurable improvements in skin hydration, joint mobility, and bone density. DSM-Firmenich's April 2025 launch of SYN-COLL CB peptide, a bioactive ingredient targeting collagen synthesis at the cellular level, illustrates the shift from commodity gelatin to precision peptides with documented efficacy. This trend is accelerating the adoption of dietary supplements among evidence-driven consumers. Food and beverages represent an emerging but high-potential application, with collagen-fortified products such as protein bars, coffee creamers, and functional waters gaining traction in mainstream retail markets in Germany and the Netherlands. Pharmaceutical applications remain niche, focusing on wound-healing matrices and tissue-engineering scaffolds, but are attracting research and development (R&D) investment as advancements in regenerative medicine continue. Animal nutrition, the smallest segment, is experiencing growth as pet food manufacturers incorporate collagen peptides into joint-health formulations for aging pets, mirroring trends observed in human supplements.

The growth of dietary supplements is further supported by telemedicine platforms and personalized nutrition apps, which bundle collagen with DNA-based dietary recommendations. These platforms bypass traditional retail channels, enabling brands to capture higher margins. Regulatory clarity under European Union (EU) Regulation 1924/2006 on nutrition and health claims has allowed brands to communicate specific benefits such as "supports skin elasticity" or "maintains joint flexibility" without triggering enforcement actions. This has reduced compliance risks that previously deterred investment in the segment. Personal care and cosmetics applications face challenges from the "beauty-from-within" movement, which promotes ingestible collagen as more effective than topical formulations. This perspective emphasizes the systemic delivery of peptides.

Geography Analysis

Germany accounted for 33.82% of European collagen revenue in 2025, supported by the manufacturing presence of Gelita and Evonik, along with a consumer base that emphasizes clinical evidence and quality certifications. Germany's market dominance is attributed to vertical integration, with Gelita managing bovine sourcing, gelatin production, and peptide hydrolysis within a single supply chain, enabling cost efficiency and faster innovation cycles. Evonik's February 2024 partnership with Jland Biotech to co-develop collagen peptides for the Asian market highlights a strategic focus on export-led growth, though European operations remain the primary profit center. The Netherlands benefits from the presence of DSM-Firmenich's headquarters and a population inclined toward preventive health measures, while Belgium and Sweden, while smaller markets in absolute terms, demonstrate high per-capita consumption due to clean-label preferences and strong regulatory frameworks ensuring product safety.

Spain is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.32% through 2031, driven by increasing disposable incomes, the integration of collagen-fortified functional foods into the Mediterranean diet, and a growing nutricosmetics culture influenced by French and Italian beauty trends. Spain's rapid growth is fueled by a wellness culture driven by tourism and the rise of direct-to-consumer brands leveraging social media to target younger demographics. France and Italy, traditionally strong in topical skincare, are shifting toward ingestible beauty products as dermatologists publish peer-reviewed studies linking oral collagen peptides to improvements in skin hydration and wrinkle depth. France's nutricosmetics market, valued at over EUR 500 million annually, is transitioning from niche to mainstream as pharmacy chains allocate shelf space to ingestible beauty products. Italy's collagen market remains fragmented, with regional players such as Italgel and Lapi Gelatine competing against multinational companies, though consolidation is expected as distribution efficiencies favor larger players.

The United Kingdom, despite regulatory changes following Brexit, remains a key market due to high supplement penetration rates and the influence of Informed Sport certification, which appeals to fitness-focused consumers. Poland's growth, though constrained by lower per-capita incomes, is accelerating as Western European brands expand into Eastern Europe. The Rest of Europe category, which includes Eastern European markets like the Czech Republic, Romania, and Hungary, is expanding from a low base as disposable incomes increase and Western supplement brands establish distribution partnerships with local retailers. These markets are witnessing gradual growth as consumers adopt preventive health measures and collagen-based products. Overall, the European collagen market reflects diverse growth dynamics, with established markets focusing on innovation and emerging markets benefiting from rising incomes and increased product availability.

Regulatory Landscape

In Europe, collagen and collagen-derived ingredients for human consumption fall under EU food hygiene and animal-origin rules. Production and raw material requirements are anchored in Regulation (EC) No 852/2004 (general food hygiene) and Regulation (EC) No 853/2004 (specific hygiene rules for food of animal origin). These requirements shape plant approvals, HACCP implementation, and sourcing controls for animal-derived inputs, including hides, skins, bones, and fish byproducts, used in collagen and gelatin manufacturing.

Access for new collagen inputs is also governed by the Novel Food framework under Regulation (EU) 2015/2283, with EFSA safety assessments. In May 2026, the European Commission authorized egg membrane collagen peptides as a novel food under Regulation (EU) 2026/1427, following an EFSA NDA opinion in 2025 that supported safe use in food supplements at a specified maximum daily intake. The authorization includes time-bound applicant protection provisions. On the trade side, imports of animal-origin collagen products, including collagen casings, require updated official certification and documentation, with Delegated Regulation (EU) 2025/637 reflecting ongoing updates to certification and CN/HS-linked requirements for entry into the Union market.

Value Chain Analysis

The European collagen value chain starts with raw material collection from meat and fish processing streams, primarily bones, hides, skins, tendons, and other connective tissues, then moves into rendering and preprocessing before extraction and hydrolysis. Collagen and gelatin processors convert these inputs into gelatin, hydrolyzed collagen, and specialized peptide fractions using controlled extraction, filtration, concentration, drying, and enzymatic hydrolysis steps, followed by blending, standardization, and packaging. EU hygiene requirements for animal-origin foods, notably Regulation (EC) No 853/2004, make plant approval status, HACCP systems, and competent-authority audits key operational checkpoints.

Downstream, ingredient distributors and specialty suppliers sell standardized collagen and peptide inputs to dietary supplement brands, food and beverage manufacturers, including functional dairy and ready-to-drink, and personal care and cosmetics formulators. Traceability and third-party certifications have become more prominent for premium positioning. Industry bodies such as the Gelatine Manufacturers of Europe (GME), representing major European producers with a sizable share of global gelatine output, support standardization and trade facilitation efforts alongside global initiatives such as GROW. The chain also depends on cross-border movement of animal-origin inputs and finished products, with EU exposure to import requirements and health certification rules for raw materials and products entering the Union, reinforcing the need for documented sourcing, microbiological controls, and batch-level traceability among players such as GELITA AG, PB Leiner, Lapi Gelatine S.p.A., and DCP B.V.

Market Opportunities and Future Outlook

Product innovation around bioavailability and format convenience is creating more room for differentiated collagen beyond commodity offerings, especially in ultra-low molecular weight peptides and ready-to-drink delivery systems. In May 2026, Weishardt launched Naticol UltraPeptide as an ultra-low molecular weight marine collagen (500 Daltons), reinforcing premiumization around absorption-focused specifications and proprietary enzymatic processing. At the same time, mainstream food and beverage integration is widening where collagen can be used, supported by the January 2026 launch in Spain of Puleva Vita Calcio Colageno by Lactalis with Bioiberica's native type II collagen (Collavant n2), which brings joint-health positioning into a mass dairy format rather than a specialist supplement-only channel.

Portfolio differentiation is also shifting toward functional blends and claim-adjacent use cases. Rousselot's June 2026 emphasis on whey-collagen peptide blends shows how suppliers use formulation systems to manage input-cost pressures while expanding the functionality narrative for finished-product manufacturers. Consolidation and scale-building continue to reshape procurement and manufacturing economics across bovine and porcine sourcing. The Darling Ingredients and Tessenderlo combination of Rousselot and PB Leiner (announced in 2025 and progressing through 2026 clearances) provides a route toward harmonized portfolios and broader multi-site production footprints, which can help maintain consistent specifications, service levels, and cross-category innovation across food, supplements, and personal care.